0001209191-21-017484.txt : 20210303
0001209191-21-017484.hdr.sgml : 20210303
20210303202007
ACCESSION NUMBER: 0001209191-21-017484
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210301
FILED AS OF DATE: 20210303
DATE AS OF CHANGE: 20210303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nabulsi Azmi
CENTRAL INDEX KEY: 0001791412
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39094
FILM NUMBER: 21711988
MAIL ADDRESS:
STREET 1: C/O PHATHOM PHARMACEUTICALS, INC.
STREET 2: 2150 E. LAKE COOK ROAD, SUITE 800
CITY: BUFFALO GROVE
STATE: IL
ZIP: 60089
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001783183
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824151574
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (877) 742-8466
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-01
0
0001783183
Phathom Pharmaceuticals, Inc.
PHAT
0001791412
Nabulsi Azmi
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102
FLORHAM PAK
NJ
07932
0
1
0
0
Chief Operating Officer
Common Stock
2021-03-01
4
S
0
3825
45.7696
D
805375
I
By Trust
Common Stock
2021-03-01
4
S
0
1548
46.0549
D
803827
I
By Trust
Common Stock
2021-03-02
4
S
0
600
44.595
D
803227
I
By Trust
Common Stock
2021-03-02
4
S
0
4833
46.1576
D
798394
I
By Trust
Common Stock
2021-03-02
4
S
0
24
46.73
D
798370
I
By Trust
Common Stock
2021-03-02
4
S
0
1600
45.1722
D
796770
I
By Trust
Common Stock
2021-03-02
4
S
0
2070
46.2293
D
794700
I
By Trust
Common Stock
453
D
Common Stock
379.87
I
By 401(k)Plan
All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.96. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.99 to $46.13. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $44.88. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.66 to $46.56. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.76 to $45.55. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.81 to $46.57. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares were acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan on January 14, 2021.
/s/ Larry Miller, Attorney-in-Fact for Azmi Nabulsi
2021-03-03